Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs

3:00 PM - 3:55 PM (EST), Tuesday, February 11, 2020 ・ Lyceum Complex
In recent months, the exits of several large companies from the neuroscience space, optimistic turnarounds in clinical development in Alzheimer’s disease, and the persistence of the opioid addiction crisis are signifying the true difficulties of developing drugs for the brain.  With millions already suffering with CNS disorders and millions more expected to be diagnosed in the next decade, accelerated by the growing population of elderly, new treatment options are needed.  What companies and which investors are rising to the challenge to bring treatments to the market?  Hear from the biotech executives and investors involved in late-stage CNS drug development as they share insights into obstacles they've encountered and solutions they've developed to address the unmet needs in CNS disorders.
Moderator
photo
Principal, Private Equity
Sofinnova
Speakers
photo
CEO
Opiant Pharmaceuticals
photo
Chairman & CEO
Tetra Therapeutics
photo
Chief Business Officer
Impel NeuroPharma
photo
President and CEO
Anavex Life Sciences Corp.
photo
Chief Operating and Business Officer and Head of Commercial Development
AZTherapies, Inc.